What are the appropriate dosing, contraindications, and monitoring recommendations for doxepin in insomnia and major depressive disorder?

Doxepin: Dosing, Contraindications, and Monitoring

For insomnia, use low-dose doxepin (3-6 mg) specifically for sleep maintenance problems, not as a first-line agent; for major depressive disorder, start at 75 mg daily and titrate to 75-150 mg daily, with maximum doses up to 300 mg in severe cases.

Insomnia Management

Positioning in Treatment Algorithm

Doxepin is not a first-line agent for insomnia. The recommended treatment sequence is 1, 2:

1. First-line: Short-intermediate acting benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon) or ramelteon
2. Second-line: Alternate BzRA or ramelteon if initial agent unsuccessful
3. Third-line: Sedating antidepressants including doxepin (especially when comorbid depression/anxiety present)

Dosing for Insomnia

Low-dose doxepin (3-6 mg) is FDA-approved specifically for sleep maintenance insomnia 2, 3:

• Indication: Sleep maintenance problems (wake after sleep onset), not sleep onset latency 2, 4
• Dose: 3 mg or 6 mg taken 30 minutes before bedtime 3, 4
• Elderly/debilitated: Start with 3 mg 3
• Mechanism: Selective H1-receptor antagonism at these low doses 4, 5

Critical distinction: These low doses (3-6 mg) are completely different from antidepressant doses and work through different mechanisms 1. The evidence shows doxepin 3-6 mg improves total sleep time, sleep efficiency, and wake after sleep onset, with effects evident after a single dose and maintained for up to 12 weeks 4, 5.

Evidence Quality

The 2017 AASM guideline provides a weak recommendation for doxepin based on low-quality evidence, noting benefits outweigh harms 2. However, the 2008 guideline explicitly states that antidepressants like doxepin used for insomnia are not FDA-approved for this indication and efficacy is not well established when used alone 1.

Important caveat: One retrospective study found low-dose doxepin did not improve sleep onset or maintenance in patients with major depressive disorder, contrasting with results in primary insomnia 6. This suggests low-dose doxepin may be ineffective when depression is the primary diagnosis.

Major Depressive Disorder

Dosing for Depression

Standard antidepressant dosing 3:

• Starting dose: 75 mg daily for mild-moderate illness
• Optimal range: 75-150 mg daily
• Severe illness: May require up to 300 mg daily (titrate gradually)
• Very mild symptoms: 25-50 mg daily may suffice
• Administration: Can be given once daily (maximum 150 mg) at bedtime, or divided doses
• Time to effect: Anti-anxiety effects appear first; full antidepressant effect takes 2-3 weeks 3

Elderly patients: Start at low end of dosing range (25 mg), titrate cautiously due to increased risk of confusion and oversedation 3

Important Limitation

Low-dose doxepin (used for insomnia) does NOT constitute adequate treatment for major depression in patients with comorbid insomnia 1. Full antidepressant doses are required.

Contraindications and Precautions

Absolute Contraindications (from FDA labeling) 3:

• Glaucoma: Risk of angle-closure attack in patients with anatomically narrow angles without patent iridectomy 3
• Urinary retention: Anticholinergic effects
• MAO inhibitor use: Standard tricyclic contraindication

Major Warnings 3:

Black Box Warning - Suicidality:

• Increased risk of suicidal thinking/behavior in children, adolescents, and young adults (ages <24) with major depressive disorder
• Monitor closely for clinical worsening, suicidality, and unusual behavior changes, especially during initial months and dose changes
• Not approved for use in children <12 years 3

Cardiovascular risks:

• QRS prolongation on ECG (>0.10 seconds indicates severe toxicity in overdose) 3
• Hypotension, hypertension, tachycardia reported 3
• Use with extreme caution in cardiac disease

Anticholinergic effects: Dry mouth, blurred vision, constipation, urinary retention 3

CNS effects: Drowsiness (most common), confusion, disorientation, hallucinations, seizures 3

Special Populations

Elderly:

• Start low doses, titrate slowly
• Higher risk of confusion, oversedation, falls
• Increased sensitivity to anticholinergic effects 3

Hepatic/renal impairment: Dose reduction required; extent of renal excretion not fully determined 3

Pregnancy: No established safety; apnea and drowsiness reported in nursing infant 3

Monitoring Recommendations

For Insomnia Treatment 1:

• Initial phase: Follow-up every few weeks to assess effectiveness, side effects, and ongoing need
• Ongoing: Regular assessment for:
  • Treatment effectiveness
  • Adverse effects (especially daytime sedation)
  • Signs of tolerance or dependence
  • Emergence of new/worsening comorbid conditions

For Depression Treatment 3:

• Suicidality monitoring: Close observation for clinical worsening, suicidal ideation, and behavioral changes, especially:

  • First few months of treatment
  • During dose adjustments (increases or decreases)
  • Watch for: anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, mania

• Cardiovascular: Monitor for hypotension, tachycardia, ECG changes if indicated

• Anticholinergic effects: Assess for dry mouth, constipation, urinary retention, blurred vision

• Withdrawal symptoms: Gradual taper required; abrupt discontinuation can cause withdrawal (not addiction) 3

Laboratory Monitoring

No routine laboratory monitoring required for low-dose insomnia treatment 3. For antidepressant doses, consider baseline ECG in patients with cardiac risk factors.

Key Clinical Pitfalls

1. Don't confuse low-dose (3-6 mg) with antidepressant doses (75-300 mg) - completely different mechanisms and indications

2. Don't use low-dose doxepin for sleep onset problems - evidence supports only sleep maintenance 2, 4

3. Don't use low-dose doxepin as monotherapy for depression with insomnia - inadequate antidepressant effect 1

4. Don't use as first-line for primary insomnia - BzRAs and ramelteon preferred 1, 2

5. Don't prescribe large quantities - overdose risk with tricyclics is significant; cardiac dysrhythmias, seizures, and death can occur 3

6. Don't combine with alcohol or other CNS depressants - additive psychomotor impairment 1

7. Don't stop abruptly after prolonged use - taper gradually to avoid withdrawal symptoms 3